Painful Diabetic Neuropathy | Current Treatment | US | 2016
Using national patient-level claims data, this report analyzes physician adherence to the treatment guidelines by exploring the use of key therapies in the newly diagnosed and recently treated patient populations. Considering newly diagnosed patients, the report provides a quantitative analysis of treatment patterns and share by line of therapy, as well as progression between lines, duration of treatment on each line, and use of concomitant treatment. With respect to recently treated patients, the report quantifies a drug’s source of business compared with its competitors and details which drugs precede others through an analysis of add-versus-switch patterns. Additional analyses explore persistency and compliance by brand.
Related Market Assessment Reports
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (EU5)
Across the EU5, the treatment landscape for major depressive disorder (MDD) is shaped by the widespread use of SSRIs and SNRIs, which continue to serve as firstline therapy due to their…
